Answers are grounded in this paper and cite their sources.
Demonstrates HIF-2α influences DNA repair in ccRCC, suggesting targeted therapies.
In clear cell renal cell carcinoma (ccRCC), aberrant accumulation of hypoxia-inducible factor-2α (HIF-2α) due to VHL gene mutation is a central event driving tumorigenesis and progression. Although DNA damage is a hallmark of renal cancer development, it remains unclear whether and how HIF-2α regulates downstream targets to modulate the DNA damage and repair process. Here, we demonstrate that HIF-2α transcriptionally activates TRIB3 expression. Further we found that TRIB3 interacts with PARP1, a key DNA repair protein, and enhances nuclear PARP1 stability by inhibiting its K63-linked polyubiquitination, thereby promoting the DNA repair capacity of ccRCC cells. Both in vitro and in vivo, the HIF-2α inhibitor belzutifan (PT2977) effectively suppressed this signaling axis and reversed the tumor-promoting effects caused by PARP1 overexpression. Collectively, our findings elucidate a critical role for the HIF-2α/TRIB3/PARP1 axis in ccRCC progression, revealing potential therapeutic targets and rational combination strategies for this disease.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: